SAIC Announces First Quarter of Fiscal Year 2025 Results
- Revenues of
$1.85 billion ; 0.4% organic growth; organic growth reflects impacts of divestitures - Net income of
$77 million ; Adjusted EBITDA(1) of$166 million or 9.0% of revenues - Diluted earnings per share of
$1.48 ; Adjusted diluted earnings per share(1) of$1.92 - Cash flows provided by operating activities of
$98 million ; Transaction-adjusted free cash flow(1) of$21 million - Net bookings of
$2.6 billion ; book-to-bill ratio of 1.4 - Company reaffirms Fiscal Year 2025 financial guidance
“We reported solid financial results in the quarter as we began executing against our enterprise growth strategy introduced at SAIC's 2024 Investor Day,” said SAIC CEO
First Quarter of Fiscal Year 2025: Summary Operating Results |
||||||||||
|
Three Months Ended |
|||||||||
|
2024 |
|
Percent change |
|
2023 |
|||||
|
(in millions, except per share amounts) |
|||||||||
Revenues |
$ |
1,847 |
|
|
(9 |
)% |
|
$ |
2,028 |
|
Operating income |
|
131 |
|
|
(17 |
)% |
|
|
157 |
|
Operating income as a percentage of revenues |
|
7.1 |
% |
|
-60 bps |
|
|
7.7 |
% |
|
Adjusted operating income(1) |
|
159 |
|
|
(12 |
)% |
|
|
181 |
|
Adjusted operating income as a percentage of revenues |
|
8.6 |
% |
|
-30 bps |
|
|
8.9 |
% |
|
Net income |
|
77 |
|
|
(21 |
)% |
|
|
98 |
|
EBITDA(1) |
|
167 |
|
|
(14 |
)% |
|
|
194 |
|
EBITDA as a percentage of revenues |
|
9.0 |
% |
|
-60 bps |
|
|
9.6 |
% |
|
Adjusted EBITDA(1) |
|
166 |
|
|
(12 |
)% |
|
|
189 |
|
Adjusted EBITDA as a percentage of revenues |
|
9.0 |
% |
|
-30 bps |
|
|
9.3 |
% |
|
Diluted earnings per share |
$ |
1.48 |
|
|
(17 |
)% |
|
$ |
1.79 |
|
Adjusted diluted earnings per share(1) |
$ |
1.92 |
|
|
(10 |
)% |
|
$ |
2.14 |
|
Net cash provided by operating activities |
$ |
98 |
|
|
20 |
% |
|
$ |
82 |
|
Free cash flow(1) |
$ |
13 |
|
|
(83 |
)% |
|
$ |
76 |
|
Transaction-adjusted free cash flow(1) |
$ |
21 |
|
|
(72 |
)% |
|
$ |
76 |
|
First Quarter Summary Results
Revenues for the quarter decreased
Operating income as a percentage of revenues decreased from the comparable prior year period primarily due to the sale of the Supply Chain Business in the prior year, a gain recognized from the deconsolidation of FSA in the prior year period, and contract completions, partially offset by ramp up in volume on existing and new contracts.
Adjusted EBITDA(1) as a percentage of revenues for the quarter decreased to 9.0% from 9.3% for the same period in the prior year primarily due to contract completions, partially offset by ramp up in volume on existing and new contracts.
Diluted earnings per share for the quarter was
Effective
Cash Generation and Capital Deployment
Cash flows provided by operating activities for the first quarter increased
During the quarter, SAIC deployed
Quarterly Dividend Declared
As previously announced, subsequent to quarter end, the Company's Board of Directors declared a cash dividend of
Backlog and Contract Awards
Net bookings for the quarter were approximately
Notable New Awards:
Special Operations Command: During the quarter, SAIC was awarded a significant modernization role on the recently awarded
Notable Recompete Awards:
Other
SAIC launched a multi-year growth strategy at 2024 Investor Day and met with key analysts and shareholders to share the company’s new vision for strategic growth to increase its value for customers and stakeholders. SAIC has committed to growing the company through a phased approach that focuses on building the company's portfolio and go-to-market approach, enhancing the brand and further developing a winning culture.
SAIC appointed Srinivas “Srini” Attili as executive vice president,
SAIC was recognized as a Leader in the IDC MarketScape:
Fiscal Year 2025 Guidance
Management reaffirms fiscal year 2025 guidance which represents the Company's views as of
|
Fiscal Year |
|
2025 Guidance |
Revenue |
|
Adjusted EBITDA(1) |
|
Adjusted EBITDA Margin(1) |
9.2% - 9.4% |
Adjusted Diluted EPS(1) |
|
Free Cash Flow(1) |
|
Webcast Information
SAIC management will discuss operations and financial results in an earnings conference call beginning at
About SAIC
SAIC® is a premier Fortune 500® technology integrator focused on advancing the power of technology and innovation to serve and protect our world. Our robust portfolio of offerings across the defense, space, civilian and intelligence markets includes secure high-end solutions in mission IT, enterprise IT, engineering services and professional services. We integrate emerging technology, rapidly and securely, into mission critical operations that modernize and enable critical national imperatives.
We are approximately 24,000 strong; driven by mission, united by purpose, and inspired by opportunities. SAIC is an Equal Opportunity Employer, fostering a culture of diversity, equity and inclusion, which is core to our values and important to attract and retain exceptional talent. Headquartered in
GAAP to Non-GAAP Guidance Reconciliation
The Company does not provide a reconciliation of forward-looking adjusted diluted EPS to GAAP diluted EPS, adjusted EBITDA margin to GAAP net income or transaction-adjusted free cash flow and free cash flow to GAAP net cash flows from operating activities due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because certain deductions for non-GAAP exclusions used to calculate net income and cash flows from operating activities may vary significantly based on actual events, the Company is not able to forecast GAAP diluted EPS, GAAP net income or GAAP net cash flows from operating activities with reasonable certainty. The variability of the above charges may have an unpredictable and potentially significant impact on our future GAAP financial results.
(1) |
Non-GAAP measure, see Schedule 6 for information about this measure. |
Forward-Looking Statements
Certain statements in this release contain or are based on “forward-looking” information within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “guidance,” and similar words or phrases. Forward-looking statements in this release may include, among others, estimates of future revenues, operating income, earnings, earnings per share, charges, total contract value, backlog, outstanding shares and cash flows, as well as statements about future dividends, share repurchases and other capital deployment plans. Such statements are not guarantees of future performance and involve risk, uncertainties and assumptions, and actual results may differ materially from the guidance and other forward-looking statements made in this release as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these material differences include those discussed in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Legal Proceedings” sections of our Annual Report on Form 10-K, as updated in any subsequent Quarterly Reports on Form 10-Q and other filings with the
Schedule 1: |
|||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||
|
Three Months Ended |
||||||
|
2024 |
|
2023 |
||||
|
(in millions, except per share amounts) |
||||||
Revenues |
$ |
1,847 |
|
|
$ |
2,028 |
|
Cost of revenues |
|
1,634 |
|
|
|
1,793 |
|
Selling, general and administrative expenses |
|
85 |
|
|
|
84 |
|
(Gain) loss on divestitures, net of transaction costs |
|
— |
|
|
|
(6 |
) |
Other operating (income) expense |
|
(3 |
) |
|
|
— |
|
Operating income |
|
131 |
|
|
|
157 |
|
Interest expense, net |
|
34 |
|
|
|
32 |
|
Other (income) expense, net |
|
2 |
|
|
|
2 |
|
Income before income taxes |
|
95 |
|
|
|
123 |
|
Provision for income taxes |
|
(18 |
) |
|
|
(25 |
) |
Net income |
$ |
77 |
|
|
$ |
98 |
|
Weighted-average number of shares outstanding: |
|
|
|
||||
Basic |
|
51.6 |
|
|
|
54.3 |
|
Diluted |
|
52.1 |
|
|
|
54.8 |
|
Earnings per share: |
|
|
|
||||
Basic |
$ |
1.49 |
|
|
$ |
1.80 |
|
Diluted |
$ |
1.48 |
|
|
$ |
1.79 |
|
Schedule 2: |
|||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||
|
2024 |
|
2024 |
||
|
(in millions) |
||||
ASSETS |
|
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
49 |
|
$ |
94 |
Receivables, net |
|
934 |
|
|
914 |
Prepaid expenses and other current assets |
|
108 |
|
|
123 |
Total current assets |
|
1,091 |
|
|
1,131 |
|
|
2,851 |
|
|
2,851 |
Intangible assets, net |
|
865 |
|
|
894 |
Property, plant, and equipment, net |
|
93 |
|
|
91 |
Operating lease right of use assets |
|
148 |
|
|
152 |
Other assets |
|
202 |
|
|
195 |
Total assets |
$ |
5,250 |
|
$ |
5,314 |
LIABILITIES AND EQUITY |
|
|
|
||
Current liabilities: |
|
|
|
||
Accounts payable |
$ |
648 |
|
$ |
567 |
Accrued payroll and employee benefits |
|
287 |
|
|
370 |
Other accrued liabilities |
|
129 |
|
|
144 |
Long-term debt, current portion |
|
90 |
|
|
77 |
Total current liabilities |
|
1,154 |
|
|
1,158 |
Long-term debt, net of current portion |
|
1,993 |
|
|
2,022 |
Operating lease liabilities |
|
136 |
|
|
147 |
Deferred income taxes |
|
29 |
|
|
28 |
Other long-term liabilities |
|
179 |
|
|
174 |
Equity: |
|
|
|
||
Total stockholders' equity |
|
1,759 |
|
|
1,785 |
Total liabilities and stockholders' equity |
$ |
5,250 |
|
$ |
5,314 |
Schedule 3: |
|||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||
|
Three Months Ended |
||||||
|
2024 |
|
2023 |
||||
|
(in millions) |
||||||
Cash flows from operating activities: |
|
|
|
||||
Net income |
$ |
77 |
|
|
$ |
98 |
|
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
||||
Depreciation and amortization |
|
35 |
|
|
|
36 |
|
Deferred income taxes |
|
— |
|
|
|
(6 |
) |
Stock-based compensation expense |
|
13 |
|
|
|
12 |
|
(Gain) loss on divestitures |
|
— |
|
|
|
(7 |
) |
Other |
|
(1 |
) |
|
|
(1 |
) |
Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of divestitures: |
|
|
|
||||
Receivables |
|
(20 |
) |
|
|
(127 |
) |
Prepaid expenses and other current assets |
|
15 |
|
|
|
4 |
|
Other assets |
|
— |
|
|
|
4 |
|
Accounts payable and accrued liabilities |
|
60 |
|
|
|
113 |
|
Accrued payroll and employee benefits |
|
(83 |
) |
|
|
(43 |
) |
Operating lease assets and liabilities, net |
|
(3 |
) |
|
|
(3 |
) |
Other long-term liabilities |
|
5 |
|
|
|
2 |
|
Net cash provided by operating activities |
|
98 |
|
|
|
82 |
|
Cash flows from investing activities: |
|
|
|
||||
Expenditures for property, plant, and equipment |
|
(6 |
) |
|
|
(6 |
) |
Purchases of marketable securities |
|
(4 |
) |
|
|
(3 |
) |
Sales of marketable securities |
|
4 |
|
|
|
1 |
|
Proceeds from assets held for sale |
|
— |
|
|
|
355 |
|
Cash divested upon deconsolidation of joint venture |
|
— |
|
|
|
(8 |
) |
Other |
|
(1 |
) |
|
|
(3 |
) |
Net cash (used in) provided by investing activities |
|
(7 |
) |
|
|
336 |
|
Cash flows from financing activities: |
|
|
|
||||
Dividend payments to stockholders |
|
(20 |
) |
|
|
(21 |
) |
Principal payments on borrowings |
|
(310 |
) |
|
|
(160 |
) |
Issuances of stock |
|
4 |
|
|
|
4 |
|
Stock repurchased and retired or withheld for taxes on equity awards |
|
(103 |
) |
|
|
(88 |
) |
Proceeds from borrowings |
|
293 |
|
|
|
160 |
|
Net cash used in financing activities |
|
(136 |
) |
|
|
(105 |
) |
Net (decrease) increase in cash, cash equivalents and restricted cash |
|
(45 |
) |
|
|
313 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
103 |
|
|
|
118 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
58 |
|
|
$ |
431 |
|
Schedule 4: |
|||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||
|
Three Months Ended |
||||||
|
2024 |
|
2023 |
||||
|
(in millions) |
||||||
Revenues |
|
|
|
||||
Defense and Intelligence |
$ |
1,436 |
|
|
$ |
1,597 |
|
Civilian |
|
411 |
|
|
|
431 |
|
Total revenues |
$ |
1,847 |
|
|
$ |
2,028 |
|
|
|
|
|
||||
Operating income (loss) |
|
|
|
||||
Defense and Intelligence |
$ |
107 |
|
|
$ |
124 |
|
Civilian |
|
34 |
|
|
|
42 |
|
Corporate |
|
(10 |
) |
|
|
(9 |
) |
Total operating income |
$ |
131 |
|
|
$ |
157 |
|
|
|
|
|
||||
Operating income margin |
|
|
|
||||
Defense and Intelligence |
|
7.5 |
% |
|
|
7.8 |
% |
Civilian |
|
8.3 |
% |
|
|
9.7 |
% |
Total operating income margin |
|
7.1 |
% |
|
|
7.7 |
% |
First Quarter Defense and Intelligence Results
Revenues for the quarter decreased
Operating income and adjusted operating income(1) as a percentage of revenues decreased from the comparable prior year period primarily due to the sale of the Supply Chain Business in the prior year.
First Quarter Civilian Results
Revenues for the quarter decreased
Operating income and adjusted operating income(1) as a percentage of revenues decreased from the comparable prior year period primarily due to reduced volume.
First Quarter Corporate Results
Operating loss and adjusted operating loss(1) for the quarter increased
(1) |
Non-GAAP measure, see Schedule 6 for information about this measure. |
Schedule 5: |
|||||||||||||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||||||||||||
The estimated value of our total backlog as of the dates presented was: |
|||||||||||||||||
|
|
|
|
||||||||||||||
|
Defense and Intelligence |
|
Civilian |
|
Total SAIC |
|
Defense and Intelligence |
|
Civilian |
|
Total SAIC |
||||||
|
(in millions) |
||||||||||||||||
Funded backlog |
$ |
2,629 |
$ |
839 |
$ |
3,468 |
|
$ |
2,707 |
$ |
832 |
$ |
3,539 |
||||
Negotiated unfunded backlog |
|
17,226 |
|
2,870 |
|
20,096 |
|
|
16,316 |
|
2,908 |
|
19,224 |
||||
Total backlog |
$ |
19,855 |
$ |
3,709 |
$ |
23,564 |
|
$ |
19,023 |
$ |
3,740 |
$ |
22,763 |
||||
Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts and task orders as work is performed and excludes contract awards which have been protested by competitors until the protest is resolved in our favor. SAIC segregates backlog into two categories, funded backlog and negotiated unfunded backlog. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts, and does not include the unfunded portion of contracts where funding is incrementally appropriated or authorized by the |
Schedule 6: |
|||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||
This schedule describes the non-GAAP financial measures included in this earnings release. While we believe that these non-GAAP financial measures may be useful in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently. |
|||||||
EBITDA and Adjusted EBITDA |
|||||||
|
Three Months Ended |
||||||
|
2024 |
|
2023 |
||||
|
(in millions) |
||||||
Revenues |
$ |
1,847 |
|
|
$ |
2,028 |
|
Net income |
$ |
77 |
|
|
$ |
98 |
|
Interest expense, net and loss on sale of receivables |
|
37 |
|
|
|
35 |
|
Provision for income taxes |
|
18 |
|
|
|
25 |
|
Depreciation and amortization |
|
35 |
|
|
|
36 |
|
EBITDA(1) |
|
167 |
|
|
|
194 |
|
EBITDA as a percentage of revenues |
|
9.0 |
% |
|
|
9.6 |
% |
Acquisition and integration costs |
|
(2 |
) |
|
|
— |
|
Restructuring and impairment costs |
|
2 |
|
|
|
1 |
|
Recovery of acquisition and integration costs and restructuring and impairment costs |
|
(1 |
) |
|
|
— |
|
(Gain) loss on divestitures, net of transaction costs |
|
— |
|
|
|
(6 |
) |
Adjusted EBITDA(1) |
$ |
166 |
|
|
$ |
189 |
|
Adjusted EBITDA as a percentage of revenues |
|
9.0 |
% |
|
|
9.3 |
% |
EBITDA is a performance measure that is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. The acquisition and integration costs relate to the Company's acquisitions. The restructuring and impairment costs represent the reorganization and facilities optimization costs or impairments of long-lived assets. The recovery of acquisition and integration costs and restructuring and impairment costs relate to costs recovered through the Company's indirect rates in accordance with Cost Accounting Standards. The (gain) loss on divestitures includes gains associated with the deconsolidation of FSA and the sale of the logistics and supply chain management business, net of transaction costs. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company. |
|||||||
(1) Non-GAAP measure, see above for definition. |
Schedule 6 (continued): |
||||||||||||||||||||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
||||||||||||||||||||||||
Adjusted Operating Income |
||||||||||||||||||||||||
|
Three Months Ended |
|||||||||||||||||||||||
|
(dollars in millions) |
|||||||||||||||||||||||
|
As Reported |
|
Acquisition and integration costs |
|
Restructuring and impairment costs |
|
Recovery of acquisition and integration costs and restructuring and impairment costs |
|
Amortization of intangible assets |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||||
Defense and Intelligence |
$ |
107 |
|
|
$ |
— |
|
|
$ |
— |
|
$ |
— |
|
|
$ |
17 |
|
$ |
124 |
|
|
8.6 |
% |
Civilian |
|
34 |
|
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
12 |
|
|
46 |
|
|
11.2 |
% |
Corporate |
|
(10 |
) |
|
|
(2 |
) |
|
|
2 |
|
|
(1 |
) |
|
|
— |
|
|
(11 |
) |
|
NM |
|
Total |
$ |
131 |
|
|
$ |
(2 |
) |
|
$ |
2 |
|
$ |
(1 |
) |
|
$ |
29 |
|
$ |
159 |
|
|
8.6 |
% |
|
Three Months Ended |
|||||||||||||||||||
|
(dollars in millions) |
|||||||||||||||||||
|
As Reported |
|
Restructuring and impairment costs |
|
Amortization of intangible assets |
|
(Gain) loss on divestitures, net of transaction costs |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||
Defense and Intelligence |
$ |
124 |
|
|
$ |
— |
|
$ |
17 |
|
$ |
— |
|
|
$ |
141 |
|
|
8.8 |
% |
Civilian |
|
42 |
|
|
|
— |
|
|
12 |
|
|
— |
|
|
|
54 |
|
|
12.5 |
% |
Corporate |
|
(9 |
) |
|
|
1 |
|
|
— |
|
|
(6 |
) |
|
|
(14 |
) |
|
NM |
|
Total |
$ |
157 |
|
|
$ |
1 |
|
$ |
29 |
|
$ |
(6 |
) |
|
$ |
181 |
|
|
8.9 |
% |
Adjusted operating income is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. The acquisition and integration costs relate to the Company's acquisitions. The restructuring and impairment costs represent the reorganization and facilities optimization costs or impairments of long-lived assets. The recovery of acquisition and integration costs and restructuring and impairment costs relate to costs recovered through the Company's indirect rates in accordance with Cost Accounting Standards. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. The (gain) loss on divestitures includes gains associated with the deconsolidation of FSA and the sale of the logistics and supply chain management business, net of transaction costs. We believe that these performance measures provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company. All adjustments to operating income for the periods presented were associated with Corporate costs and initiatives. |
||||||||||||||||||||
(1) Non-GAAP measure, see above for definition. |
Schedule 6 (continued): |
||||||||||||||||||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
||||||||||||||||||||||
Adjusted Diluted Earnings Per Share |
||||||||||||||||||||||
|
Three Months Ended |
|||||||||||||||||||||
|
(dollars in millions) |
|||||||||||||||||||||
|
As Reported |
|
Acquisition and integration costs |
|
Restructuring and impairment costs |
|
Recovery of acquisition and integration costs and restructuring and impairment costs |
|
Amortization of intangible assets |
|
Non-GAAP results(1) |
|||||||||||
Income before income taxes |
$ |
95 |
|
|
$ |
(2 |
) |
|
$ |
2 |
|
$ |
(1 |
) |
|
$ |
29 |
|
|
$ |
123 |
|
Provision for income taxes |
|
(18 |
) |
|
|
— |
|
|
|
— |
|
|
— |
|
|
|
(5 |
) |
|
|
(23 |
) |
Net income |
$ |
77 |
|
|
$ |
(2 |
) |
|
$ |
2 |
|
$ |
(1 |
) |
|
$ |
24 |
|
|
$ |
100 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Diluted EPS |
$ |
1.48 |
|
|
$ |
(0.04 |
) |
|
$ |
0.04 |
|
$ |
(0.02 |
) |
|
$ |
0.46 |
|
|
$ |
1.92 |
|
|
Three Months Ended |
|||||||||||||||||
|
(dollars in millions) |
|||||||||||||||||
|
As Reported |
|
Restructuring and impairment costs |
|
Amortization of intangible assets |
|
(Gain) loss on divestitures, net of transaction costs |
|
Non-GAAP results(1) |
|||||||||
Income before income taxes |
$ |
123 |
|
|
$ |
1 |
|
$ |
29 |
|
|
$ |
(6 |
) |
|
$ |
147 |
|
Provision for income taxes |
|
(25 |
) |
|
|
— |
|
|
(6 |
) |
|
|
1 |
|
|
|
(30 |
) |
Net income |
$ |
98 |
|
|
$ |
1 |
|
$ |
23 |
|
|
$ |
(5 |
) |
|
$ |
117 |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Diluted EPS |
$ |
1.79 |
|
|
$ |
0.02 |
|
$ |
0.42 |
|
|
$ |
(0.09 |
) |
|
$ |
2.14 |
|
Adjusted diluted earnings per share is a performance measure that excludes the impact of non-recurring transactions that we do not consider to be indicative of our ongoing operating performance. The acquisition and integration costs relate to the Company's acquisitions. The restructuring and impairment costs represent the reorganization and facilities optimization costs or impairments of long-lived assets. The recovery of acquisition and integration costs and restructuring and impairment costs relate to costs recovered through the Company's indirect rates in accordance with Cost Accounting Standards. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. The (gain) on divestitures includes gains associated with the deconsolidation of FSA and the sale of the logistics and supply chain management business, net of transaction costs. Adjusted diluted earnings per share also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, we do not acquire businesses on a predictable cycle, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. We believe that this performance measure provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of the Company. |
||||||||||||||||||
(1) Non-GAAP measure, see above for definition. |
Schedule 6 (continued): |
|||||||
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION |
|||||||
Free Cash Flow and Transaction-Adjusted Free Cash Flow |
|||||||
|
Three Months Ended |
||||||
|
2024 |
|
2023 |
||||
|
(in millions) |
||||||
Net cash provided by operating activities |
$ |
98 |
|
|
$ |
82 |
|
Expenditures for property, plant, and equipment |
|
(6 |
) |
|
|
(6 |
) |
Cash provided by MARPA Facility |
|
(79 |
) |
|
|
— |
|
Free cash flow(1) |
$ |
13 |
|
|
$ |
76 |
|
L&SCM divestiture transition services |
|
8 |
|
|
|
— |
|
Transaction-adjusted free cash flow(1) |
$ |
21 |
|
|
$ |
76 |
|
|
|
FY25 Guidance |
|
|
(in millions) |
Net cash provided by operating activities |
|
|
Expenditures for property, plant, and equipment |
|
Approximately |
Free cash flow(1) |
|
|
Free cash flow is calculated by taking cash flows provided by operating activities less expenditures for property, plant, and equipment and less cash flows from our Master Accounts Receivable Purchasing Agreement (MARPA Facility) for the sale of certain designated eligible |
||
(1) Non-GAAP measure, see above for definition. |
||
Exhibit 99.2
SCIENCE APPLICATIONS INTERNATIONAL CORPORATION
UNAUDITED HISTORICAL FINANCIAL MEASURES
Background
Effective
The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the defense and intelligence departments and agencies of the United States Government.
The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.
We have prepared unaudited historical consolidated financial information based on the new reporting structure set forth below, which includes certain non-GAAP measures. Management believes that these non-GAAP measures provide another representation of the results of operations and financial condition.
Unaudited Historical Financial Measures
The following table presents revenues for fiscal 2024 and twelve months ended fiscal 2023 under the new segment structure (in millions):
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||
|
2023 |
|
2023 |
|
2023 |
|
2024 |
|
2024 |
|
2023 |
||||||
Defense and Intelligence |
$ |
1,597 |
|
$ |
1,389 |
|
$ |
1,479 |
|
$ |
1,352 |
|
$ |
5,817 |
|
$ |
5,876 |
Civilian |
|
431 |
|
|
395 |
|
|
416 |
|
|
385 |
|
|
1,627 |
|
|
1,828 |
Total |
$ |
2,028 |
|
$ |
1,784 |
|
$ |
1,895 |
|
$ |
1,737 |
|
$ |
7,444 |
|
$ |
7,704 |
The following table presents operating income for fiscal 2024 and twelve months ended fiscal 2023 under the new segment structure (in millions):
|
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||||||||
|
2023 |
|
2023 |
|
2023 |
|
2024 |
|
2024 |
|
2023 |
||||||||||||
Defense and Intelligence |
$ |
124 |
|
|
$ |
106 |
|
|
$ |
106 |
|
|
$ |
100 |
|
|
$ |
436 |
|
|
$ |
438 |
|
Civilian |
|
42 |
|
|
|
43 |
|
|
|
54 |
|
|
|
19 |
|
|
|
158 |
|
|
|
167 |
|
Corporate |
|
(9 |
) |
|
|
213 |
|
|
|
(17 |
) |
|
|
(40 |
) |
|
|
147 |
|
|
|
(104 |
) |
Total |
$ |
157 |
|
|
$ |
362 |
|
|
$ |
143 |
|
|
$ |
79 |
|
|
$ |
741 |
|
|
$ |
501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Operating income margin |
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Defense and Intelligence |
|
7.8 |
% |
|
|
7.6 |
% |
|
|
7.2 |
% |
|
|
7.4 |
% |
|
|
7.5 |
% |
|
|
7.5 |
% |
Civilian |
|
9.7 |
% |
|
|
10.9 |
% |
|
|
13.0 |
% |
|
|
4.9 |
% |
|
|
9.7 |
% |
|
|
9.1 |
% |
Total operating income margin |
|
7.7 |
% |
|
|
20.3 |
% |
|
|
7.5 |
% |
|
|
4.5 |
% |
|
|
10.0 |
% |
|
|
6.5 |
% |
The following tables present the reconciliation of operating income by reportable segment to non-GAAP operating income for fiscal 2024 and twelve months ended fiscal 2023 under the new segment structure (in millions):
|
Three Months Ended |
|||||||||||||||||||
|
GAAP results |
|
Restructuring and impairment costs |
|
Amortization of intangible assets |
|
(Gain) loss on divestitures, net of transaction costs |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||
Defense and Intelligence |
$ |
124 |
|
|
$ |
— |
|
$ |
17 |
|
$ |
— |
|
|
$ |
141 |
|
|
8.8 |
% |
Civilian |
|
42 |
|
|
|
— |
|
|
12 |
|
|
— |
|
|
|
54 |
|
|
12.5 |
% |
Corporate |
|
(9 |
) |
|
|
1 |
|
|
— |
|
|
(6 |
) |
|
|
(14 |
) |
|
NM |
|
Total |
$ |
157 |
|
|
$ |
1 |
|
$ |
29 |
|
$ |
(6 |
) |
|
$ |
181 |
|
|
8.9 |
% |
|
Three Months Ended |
|||||||||||||||||||||
|
GAAP results |
|
Acquisition and integration costs |
|
Restructuring and impairment costs |
|
Amortization of intangible assets |
|
(Gain) loss on divestitures, net of transaction costs |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||
Defense and Intelligence |
$ |
106 |
|
$ |
— |
|
$ |
— |
|
$ |
17 |
|
$ |
— |
|
|
$ |
123 |
|
|
8.9 |
% |
Civilian |
|
43 |
|
|
— |
|
|
— |
|
|
12 |
|
|
— |
|
|
|
55 |
|
|
13.9 |
% |
Corporate |
|
213 |
|
|
1 |
|
|
5 |
|
|
— |
|
|
(234 |
) |
|
|
(15 |
) |
|
NM |
|
Total |
$ |
362 |
|
$ |
1 |
|
$ |
5 |
|
$ |
29 |
|
$ |
(234 |
) |
|
$ |
163 |
|
|
9.1 |
% |
|
Three Months Ended |
|||||||||||||||||||
|
GAAP results |
|
Restructuring and impairment costs |
|
Recovery of restructuring and impairment costs |
|
Amortization of intangible assets |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||
Defense and Intelligence |
$ |
106 |
|
|
$ |
— |
|
$ |
— |
|
|
$ |
16 |
|
$ |
122 |
|
|
8.2 |
% |
Civilian |
|
54 |
|
|
|
— |
|
|
— |
|
|
|
12 |
|
|
66 |
|
|
15.9 |
% |
Corporate |
|
(17 |
) |
|
|
2 |
|
|
(1 |
) |
|
|
— |
|
|
(16 |
) |
|
NM |
|
Total |
$ |
143 |
|
|
$ |
2 |
|
$ |
(1 |
) |
|
$ |
28 |
|
$ |
172 |
|
|
9.1 |
% |
|
Three Months Ended |
|||||||||||||||||||
|
GAAP results |
|
Restructuring and impairment costs |
|
Recovery of restructuring and impairment costs |
|
Amortization of intangible assets |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||
Defense and Intelligence |
$ |
100 |
|
|
$ |
— |
|
$ |
— |
|
|
$ |
17 |
|
$ |
117 |
|
|
8.7 |
% |
Civilian |
|
19 |
|
|
|
— |
|
|
— |
|
|
|
12 |
|
|
31 |
|
|
8.1 |
% |
Corporate |
|
(40 |
) |
|
|
15 |
|
|
(5 |
) |
|
|
— |
|
|
(30 |
) |
|
NM |
|
Total |
$ |
79 |
|
|
$ |
15 |
|
$ |
(5 |
) |
|
$ |
29 |
|
$ |
118 |
|
|
6.8 |
% |
|
Twelve Months Ended |
|||||||||||||||||||||||||
|
GAAP results |
|
Acquisition and integration costs |
|
Restructuring and impairment costs |
|
Recovery of acquisition and integration costs and restructuring and impairment costs |
|
Amortization of intangible assets |
|
(Gain) loss on divestitures, net of transaction costs |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
|||||||||||
Defense and Intelligence |
$ |
436 |
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
$ |
67 |
|
$ |
— |
|
|
$ |
503 |
|
|
8.6 |
% |
Civilian |
|
158 |
|
|
— |
|
|
— |
|
|
— |
|
|
|
48 |
|
|
— |
|
|
|
206 |
|
|
12.7 |
% |
Corporate |
|
147 |
|
|
1 |
|
|
23 |
|
|
(6 |
) |
|
|
— |
|
|
(240 |
) |
|
|
(75 |
) |
|
NM |
|
Total |
$ |
741 |
|
$ |
1 |
|
$ |
23 |
|
$ |
(6 |
) |
|
$ |
115 |
|
$ |
(240 |
) |
|
$ |
634 |
|
|
8.5 |
% |
|
Twelve Months Ended |
||||||||||||||||||||||
|
GAAP results |
|
Acquisition and integration costs |
|
Restructuring and impairment costs |
|
Recovery of acquisition and integration costs and restructuring and impairment costs |
|
Amortization of intangible assets |
|
Non-GAAP results(1) |
|
Non-GAAP operating margin(1) |
||||||||||
Defense and Intelligence |
$ |
438 |
|
|
$ |
— |
|
$ |
— |
|
$ |
— |
|
|
$ |
69 |
|
$ |
507 |
|
|
8.6 |
% |
Civilian |
|
167 |
|
|
|
— |
|
|
— |
|
|
— |
|
|
|
56 |
|
|
223 |
|
|
12.2 |
% |
Corporate |
|
(104 |
) |
|
|
13 |
|
|
24 |
|
|
(12 |
) |
|
|
— |
|
|
(79 |
) |
|
NM |
|
Total |
$ |
501 |
|
|
$ |
13 |
|
$ |
24 |
|
$ |
(12 |
) |
|
$ |
125 |
|
$ |
651 |
|
|
8.5 |
% |
(1) |
Non-GAAP measure, see Schedule 6 for information about this measure. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240531081837/en/
Investor Relations:
+1.703.488.8528
joseph.w.denardi@saic.com
Media:
+1.703.676.8215
publicrelations@saic.com
Source: Science Applications International Corp.